In a prespecified secondary analysis of the phase 3 SELECT trial, once-weekly semaglutide 2.4 mg reduced high-sensitivity C-reactive protein by 37.8% versus placebo at 104 weeks among adults with...
In a post hoc analysis of the phase 3 HELIOS-B trial, vutrisiran reduced worsening of left atrial strain at 30 months among patients with transthyretin amyloidosis with cardiomyopathy.
The FDA approved a once-monthly autoinjector for Lerochol (lerodalcibep-liga) and added language to the prescribing information noting that cardiovascular outcomes trials with statins and monoclonal...
A systematic review and meta-analysis presented at the 2026 American College of Cardiology Scientific Session evaluated whether tafamidis was associated with improved survival in patients aged 80 years and...
Primary care physicians can play a critical role in recognizing transthyretin amyloid cardiomyopathy, initiating an appropriate diagnostic evaluation, coordinating treatment, and helping patients and...
July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
A meta-analysis of randomized controlled trials presented at the American College of Cardiology’s Annual Scientific Session suggests RNA therapeutics reduce mortality and cardiac failure risk in...
In a landmark survival analysis of 596 consecutive patients with transthyretin amyloid cardiomyopathy, worsening NT-proBNP and heart failure hospitalization at 6 months were independently associated with...
